Study makes first step toward genome-based chemotherapy
WASHINGTON — Researchers have taken a step toward personalizing the treatment of lung cancer.
Matching treatments to specific mutations in tumors is routine for some cancers, such as breast cancer, but until recently, chemotherapy for lung cancer has been given on a one-treatment-fits-all basis. Now, a new study, called the BATTLE trial, shows that treatments tailored for each patient’s particular type of lung cancer may improve outcomes.
Results of the Phase II trial, the first large clinical trial to test the effectiveness of a personalized approach to lung cancer, were presented April 18 during the annual meeting of the American Association for Cancer Research.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.